Personalis, Inc. (PSNL) Stock Research Report

A high-beta “Win-in-MRD” challenger betting that 1‑PPM ultra-sensitive liquid biopsy plus new Medicare coverage can turn exploding test volume into a clinical revenue inflection—and a higher diagnostics multiple.

Executive Summary

Personalis (PSNL) is a precision oncology company providing advanced genomic sequencing and analytics to support cancer management across the patient journey, spanning both biopharma research services and clinical diagnostics. Its central strategy—“Win-in-MRD”—focuses on commercializing NeXT Personal, a tumor-informed liquid biopsy assay designed for ultra-sensitive minimal residual disease detection using whole-genome sequencing. By tracking up to ~1,800 patient-specific variants and leveraging proprietary noise suppression (NeXT SENSE), the platform targets ~1 part-per-million sensitivity and very high specificity, aiming to detect recurrence earlier than imaging and improve intervention timing. Strategically, Personalis is pivoting away from lower-margin, legacy enterprise sequencing revenue toward higher-value, reimbursable clinical diagnostics. In 2025, revenue fell to $69.6M due to planned legacy wind-down, but clinical test volume surged nearly 400% to 16,233 tests—evidence of strong demand. With pivotal Medicare coverage wins in breast and lung (late 2025/early 2026) and a strong cash position (~$240M), the company is positioned for a potential revenue inflection as previously unreimbursed volumes convert into paid clinical revenue.

Full Research Report

Personalis, Inc. (PSNL) Investment Analysis

1. Executive Summary:

Personalis, Inc. (PSNL) is a commercial-stage precision oncology company specializing in advanced genomic sequencing and analytics to support the active management of cancer throughout the patient journey.[1, 2] The company operates at the intersection of liquid biopsy and high-complexity genomic profiling, providing critical data to biopharmaceutical researchers and clinical oncologists.[1, 3] Personalis generates revenue through two primary channels: biopharmaceutical testing services and clinical diagnostic testing.[4, 5] In the biopharmaceutical segment, the company partners with global drug developers to identify biomarkers, monitor treatment response, and accelerate clinical trials using its proprietary NeXT Platform.[6, 7] In the clinical segment, Personalis offers the NeXT Personal and NeXT Dx tests, which enable physicians to detect minimal residual disease (MRD) and select targeted therapies for patients with solid tumors.[1, 3]

The core of the Personalis value proposition is its "Win-in-MRD" strategy, which focuses on the commercialization of NeXT Personal, an ultra-sensitive, tumor-informed liquid biopsy assay.[4, 8, 9] While traditional ctDNA tests often struggle with low sensitivity in early-stage disease or during long-term surveillance, the NeXT Personal platform leverages whole-genome sequencing (WGS) to achieve a detection threshold of approximately 1 part per million (PPM), which is significantly more sensitive than current industry standards.[3, 10, 11] This technical superiority is designed to identify cancer recurrence months or years before traditional imaging, providing a critical window for intervention.[3, 12]

The primary customers for Personalis include major biopharmaceutical companies such as Moderna, Merck, and AstraZeneca, as well as community and academic oncologists.[5, 7, 8] The most important end markets are high-incidence solid tumors, specifically breast, lung, and colorectal cancers, which represent a combined annual addressable market in the billions of dollars.[8, 13, 14] Customers choose Personalis over alternatives due to its superior analytical sensitivity, its comprehensive "tumor-informed" approach that tracks up to 1,800 patient-specific variants, and its "sample-sparing" technology that requires minimal tissue and plasma input.[3, 11, 15]

The company is currently navigating a significant strategic rotation, moving away from legacy, lower-margin enterprise sequencing projects—such as its historical relationship with Natera and the VA Million Veterans Program—toward high-value, high-margin clinical diagnostic tests.[4, 5, 8] In 2025, total revenue reached $69.6 million, and while this reflected a year-over-year decline due to the planned wind-down of legacy contracts, clinical test volume surged nearly 400% to 16,233 tests.[2, 4, 16] This volume growth, coupled with pivotal Medicare coverage decisions in breast and lung cancer secured in late 2025 and early 2026, positions the company for a potential revenue inflection point as unreimbursed test volumes transition to paid clinical revenue.[4, 17, 18]

Key Feature Description
Core Technology Whole Genome Sequencing (WGS) based MRD detection [11]
Lead Product NeXT Personal (1 PPM sensitivity) [3, 10]
Market Strategy "Win-in-MRD" targeting breast, lung, and CRC [8, 14]
2025 Clinical Volume 16,233 tests (+394% YoY) [2, 4]
2026 Revenue Guidance $78 million to $80 million [4, 9]
Cash Position ~$240 million (as of Dec 31, 2025) [4, 9]

2. Business Drivers & Strategic Overview:

The strategic engine of Personalis is driven by a fundamental belief that ultra-sensitive detection of molecular residual disease (MRD) will become the standard of care for oncology management.[1, 5, 8] The company’s revenue drivers are currently transitioning from services-based income to high-value clinical diagnostic fees.[4, 5, 16] This transition is underpinned by four key growth initiatives: scaling clinical test volume, securing broad reimbursement, expanding biopharmaceutical partnerships, and maintaining a technological lead in analytical sensitivity.[1, 5, 9, 16]

Product and Service Detail: What is Being Sold

Personalis sells a sophisticated data-as-a-service model through its genomic assays.[1, 3] The flagship product, NeXT Personal, is a tumor-informed MRD assay.[3, 11] In practice, this means the company first sequences a patient's tumor tissue and matched normal blood using WGS to identify the unique "genomic fingerprint" of that individual's cancer.[15, 19] From this data, Personalis identifies up to 1,800 patient-specific somatic variants.[3, 11, 15] These variants are then tracked via blood draws (liquid biopsy) throughout the patient's journey—post-surgery (landmark), during adjuvant therapy, and during long-term surveillance.[3, 12] The product sold to the clinician is a comprehensive report indicating the presence or absence of ctDNA and the quantitative tumor burden.[6, 11]

Additionally, the company offers NeXT Dx, an ultra-comprehensive tumor profiling assay that analyzes the entire exome (20,000 genes) and transcriptome (RNA).[3, 20] This product is primarily used in advanced cancer settings to help clinicians select from FDA-approved therapies or match patients to clinical trials.[20] Unlike standard panels that may only look at 300 to 500 genes, NeXT Dx provides deep insights into RNA-based fusions and advanced biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).[20] For biopharmaceutical customers, Personalis provides the ImmunoID NeXT platform, which is an end-to-end solution for biomarker discovery, used extensively by companies like Moderna for neoantigen therapy development.[6, 7, 21]

Moat Analysis: Sustainable Competitive Advantages

The competitive moat for Personalis is characterized by significant technical barriers to entry and deep clinical validation.[4, 8, 10]

  • Technological Sensitivity (The 1 PPM Barrier): The ability to detect ctDNA at levels down to 1 PPM is the company’s primary differentiator.[3, 11] Competitors typically track 16 to 50 variants, which limits their sensitivity in early-stage disease where the volume of tumor DNA in the blood is extremely low.[10, 15] By tracking 1,800 variants, Personalis increases the statistical probability of capturing rare tumor molecules.[11, 19]
  • Proprietary Noise Suppression (NeXT SENSE): Sequencing at such high depth and breadth creates a massive amount of genomic "noise" (sequencing errors that look like mutations).[11, 19] Personalis has developed the NeXT SENSE engine, a suite of proprietary algorithms that suppress this noise, enabling 99.98% analytical specificity.[11, 12] This ensures that when a test is positive, it reflects a true cancer signal rather than a technical error.[12]
  • Intellectual Property (IP): The company maintains a robust patent estate covering its whole-genome approach to MRD and its noise-reduction methodologies.[4, 22] This IP moat was validated in 2025 by a $1.0 million royalty payment for licensed patents, demonstrating the company’s ability to defend its technical turf.[4]
  • Clinical Evidence Moat (TRACERx & VICTORI): The company’s technology is backed by longitudinal data from studies like TRACERx (lung cancer), published in Cell, which tracked patients for a median of over 5 years.[3, 13] Such long-term clinical validation is difficult for new entrants to replicate quickly, creating a high barrier for physician adoption and payer coverage.[4, 8]
  • Distribution Ecosystem (Tempus Strategic Alliance): Personalis has offloaded a significant portion of the commercial risk by partnering with Tempus AI.[14, 23] Tempus has a sales reach into over 50% of U.S. oncologists and serves as the exclusive commercial partner for NeXT Personal in breast, lung, and colorectal cancers through 2028.[14, 24] This ecosystem advantage allows Personalis to scale like a much larger company without the associated overhead of a massive direct sales force.[5, 14]

TAM / Market Opportunity Analysis

The total addressable market (TAM) for oncology precision medicine and MRD testing is vast and growing.[25] Credible industry sources suggest the U.S. MRD market alone could be worth over $20 billion annually.[8] This is based on approximately 15 million cancer survivors who require ongoing monitoring for recurrence.[14]

Segment Market Characteristic Credible Support
Breast Cancer ~300k new cases/yr in US; long surveillance window [4, 14, 17]
Lung Cancer ~230k new cases/yr in US; high recurrence risk [4, 18, 25]
Colorectal Cancer ~150k new cases/yr in US; established clinical utility [14, 26, 27]
Biopharma R&D Multi-billion dollar oncology R&D spend annually [25]

The oncology precision medicine market is expected to maintain a CAGR of approximately 9.5% through 2030, driven by the shift toward personalized cancer medicine and advancements in targeted therapies.[25] Personalis is specifically positioned to capture the "surveillance" portion of this market, which requires the highest levels of analytical sensitivity.[1, 3, 6]

Competitive Landscape: Positioning and Momentum

The MRD market is a "winner-takes-most" environment where clinical evidence and reimbursement are the primary battlegrounds.[28]

  • Natera (Signatera): The primary incumbent. Natera has the advantage of broad commercial adoption and the most extensive payer coverage to date.[13, 28, 29] However, Natera’s standard Signatera test tracks significantly fewer variants than NeXT Personal.[15, 29] Natera is responding to Personalis’ challenge by launching its own WGS-based and tissue-free assays in 2025/2026.[13, 30]
  • Guardant Health (Reveal): Primarily known for its "tissue-free" approach, which is faster but generally less sensitive for early recurrence than tumor-informed methods.[10, 13, 28] Guardant has strong Medicare coverage in colorectal cancer but is currently playing catch-up in breast and lung surveillance.[13, 31]
  • Exact Sciences: A formidable player with a massive primary care and oncology sales force, currently scaling its own MRD solutions.[28]
  • Momentum Assessment: Personalis appears to be gaining significant ground in the "clinical mindshare" segment.[5, 8, 32] The nearly 400% growth in clinical volume in 2025 suggests that the "ultra-sensitivity" narrative is resonating with physicians who find current tests lacking.[2, 4] The company is moving from a defensive position (legacy sequencing) to an aggressive offensive posture (clinical MRD expansion).[4, 5]

SENSITIVITY-DRIVEN MARKET DISRUPTION

3. Financial Performance & Valuation:

The financial narrative for Personalis in 2025 is one of "revenue rotation" and strategic investment.[4, 5, 16] While the headline revenue figures showed a decline, the underlying metrics indicate a shift toward higher-value clinical activity.[4, 5]

2025 Historical Performance and Key Metrics

Total revenue for 2025 was $69.6 million, compared to $84.6 million in 2024.[4, 9] This 17.7% decline was anticipated and driven by the intentional wind-down of legacy contracts.[7, 8, 16] Specifically, revenue from Natera dropped by $19.5 million, and population sequencing for the VA MVP declined significantly.[8, 16] However, this "top-line" decline masks a fundamental improvement in the business model's future earning power.[4, 5]

Metric FY 2024 FY 2025 YoY Change
Total Revenue $84.6M $69.6M -17.7% [4, 9]
Clinical Test Revenue $0.8M $2.0M +150% [2, 4]
Clinical Test Volume 3,285 16,233 +394% [2, 4, 16]
Gross Margin 32.0% 22.7% -9.3pp [5, 8, 33]
Net Loss $81.3M $81.3M Flat [7, 9, 16]
Ending Cash/Investments $185.0M $240.0M +29.7% [4, 7, 9]

The most important financial driver currently is the "unreimbursed volume".[5, 16] In Q4 2025, the company delivered 6,183 clinical tests but only recognized $0.9 million in clinical revenue.[4, 9] This implies an average recognized price per clinical test of approximately $145, far below the Medicare reimbursement rate of $4,266 for the NeXT Personal monitoring test.[17, 34] As Medicare payments begin to process for tests performed after the coverage effective dates (late 2025/early 2026), each unit of volume will generate significantly more revenue, driving a potential "revenue explosion" relative to volume.[4, 9, 17, 35]

Current Valuation Multiples and Financial Drivers

As Personalis is currently unprofitable, valuation is driven by its Price-to-Sales (P/S) and Enterprise Value-to-Revenue (EV/Rev) multiples, as well as its path to cash flow break-even.[36, 37, 38]

  • P/S Ratio: Based on 2025 revenue, the P/S is approximately 9.87x.[36] However, the market is forward-looking toward the 2026 revenue inflection.
  • Forward EV/Revenue: Based on 2026 revenue guidance of $79 million (midpoint), the forward EV/Revenue multiple is roughly 7.6x (assuming an EV of ~$600M).[4, 22, 37, 38, 39]
  • Valuation Connection to Core Business Model: The core driver for valuation is the transformation of the revenue mix.[4, 5] High-margin clinical diagnostic companies typically trade at 10x to 15x revenue, while low-margin genomic service providers trade at 2x to 4x.[37, 40, 41] As clinical revenue moves from 3% of total revenue in 2025 to a projected 13% in 2026, and higher in subsequent years, the blended multiple for the company should expand significantly.[4, 5, 9, 16]

Cash Usage and Capital Structure

The company’s balance sheet is a critical asset in the current risk-off macro environment.[4, 9] Personalis raised $109 million in 2025 via an ATM program at a weighted-average price of $8.43 per share, ending the year with $240 million.[1, 4] Management expects to use approximately $100 million in cash in 2026 to fund clinical expansion and R&D.[4, 5, 9] This provides a clear runway through 2027, by which time the company expects its higher-margin clinical revenue to begin significantly offsetting its operating losses.[4, 5, 7]

REIMBURSEMENT DRIVES MULTIPLE EXPANSION

4. Risk Assessment & Macroeconomic Considerations:

Personalis is a high-beta, clinical-stage diagnostics company, and its investment thesis is subject to multiple layers of execution and structural risk.[2, 5, 16]

Company-Specific Execution Risks

The primary risk is a failure to convert clinical test volume into paid revenue.[5, 16] While securing Medicare coverage is a monumental milestone, the "billing and collections" phase in specialized diagnostics is notoriously difficult.[9] Any delays in the processing of claims or a failure to secure contracts with major private insurers (UnitedHealthcare, Anthem, etc.) would leave the company with high operational costs and stagnant revenue.[1, 5, 8] Furthermore, the company’s reliance on Tempus for over 50% of its clinical commercial reach creates a "single point of failure" risk.[14, 23] If the Tempus relationship were to terminate or if Tempus were to launch a competing product, Personalis would struggle to maintain its volume growth.[2, 14, 24]

Competitive and Industry Structure Risks

The MRD industry is rapidly maturing, and Personalis faces an "incumbency moat" from Natera.[28, 29] Natera’s broad adoption and established workflow within oncology clinics make it difficult for physicians to switch, even if NeXT Personal is technically superior.[5, 28] Additionally, the industry is moving toward "tissue-free" testing.[13] If tissue-free tests achieve sensitivity parity with tumor-informed tests, Personalis’ whole-genome, tissue-based approach could become viewed as overly complex or slow, despite its current technical edge.[10, 11]

Regulatory and Legal Risks

The FDA has historically exercised enforcement discretion over Laboratory Developed Tests (LDTs), but this is changing.[2, 42] New FDA regulations requiring formal Premarket Approval (PMA) for tests like NeXT Personal could significantly increase R&D costs and time-to-market for new indications.[42] On the legal side, patent litigation is common in the genomics space. While Personalis is currently a royalty receiver, it could find itself on the defensive if competitors challenge its noise-suppression or WGS patents.[4, 22]

Balance Sheet and Capital Allocation Risks

With a $100 million projected cash burn in 2026, the company is effectively in a race against time to reach cash-flow break-even before its $240 million cash pile is exhausted.[4, 9] A failure to reach profitability by early 2028 would force a dilutive capital raise in potentially unfavorable market conditions.[4, 7] The company’s decision to continue providing unreimbursed tests to "build the market" is a high-risk capital allocation strategy; if coverage expansion is delayed, this investment may never generate a return.[5, 8, 16]

Macroeconomic Sensitivities

  • Geopolitical and Macro Volatility: Recent market action has shown that PSNL is highly sensitive to geopolitical shocks (e.g., U.S.-Iran conflict) and interest rate expectations.[43, 44] As an unprofitable growth stock, its valuation is crushed in risk-off environments.[43]
  • Biopharma Spending: A slowdown in the broader biopharmaceutical sector—driven by post-COVID budget realignments or a general recession—directly impacts the "Pharma Testing" segment, which currently accounts for over 70% of revenue.[5, 8, 32, 45]

Risk Breakdown and Early Warnings

Risk Category What Could Go Wrong Early Warning Sign Damage Potential
Reimbursement Private payers refuse to follow Medicare's lead on MRD. Clinical revenue per test remains under $500 for multiple quarters. CRITICAL: Kills the path to profitability.
Competitive Natera launches a WGS test that matches 1 PPM sensitivity. Sequential decline in clinician "orders" or hospital account growth. HIGH: Neutralizes the primary technical moat.
Operational Lab turnaround times exceed 3 weeks due to WGS complexity. Increase in "unsuccessful" test rates or clinician complaints. MEDIUM: Damages the brand and Tempus partnership.
Financial 2026 cash burn exceeds $125 million. Guidance revision on cash usage during Q2 or Q3 earnings calls. HIGH: Leads to massive dilution or distressed sale.

EXECUTION IS THE HIGHEST HURDLE

5. 5-Year Scenario Analysis:

The following scenario analysis projects the potential outcomes for Personalis through 2030, using the current share price of $6.34 as a baseline for total return calculations.[43, 46]

Base Case (Probability: 55%)

In the base case, Personalis successfully navigates the transition to a clinical-first business.[4, 5] Reimbursement for breast and lung cancer scales in 2026, and the company secures Medicare coverage for Colorectal Cancer (CRC) in late 2027.[17, 18, 27] The biopharma segment stabilizes as the Moderna/Merck phase 3 melanoma trial readouts provide a new catalyst for MRD adoption in drug development.[21, 47]

  • Financial Inputs:
    • Revenue CAGR: 35%.
    • 2030 Revenue: ~$313 million.
    • Gross Margin: 55% (driven by clinical mix and scale).[5, 9, 16]
    • Shares Outstanding: 135 million (accounting for SBC and limited ATM usage).[33, 48, 49]
    • Exit Multiple: 6x EV/Revenue (standard for profitable, mid-tier diagnostics).
  • Bridge to Valuation: $313M Revenue * 6x = $1.878B EV. Adding projected 2030 cash of $100M (assuming break-even is reached in 2028/2029) leads to a $1.978B Market Cap.[4, 5, 7]

High Case (Probability: 25%)

The high case assumes NeXT Personal becomes the undisputed "Gold Standard" for ultra-sensitive surveillance.[3, 8] The 1 PPM differentiator leads to massive market share capture from Natera. The Moderna/Merck V940 vaccine is approved and mandates NeXT Personal for patient monitoring globally.[21, 47]

  • Financial Inputs:
    • Revenue CAGR: 50%.
    • 2030 Revenue: ~$530 million.
    • Gross Margin: 70%.
    • Shares Outstanding: 115 million (limited dilution, potentially starting buybacks).
    • Exit Multiple: 10x EV/Revenue (premium valuation for a market leader).
  • Bridge to Valuation: $530M Revenue * 10x = $5.3B EV. $5.3B Market Cap / 115M shares = $46.09.[36, 37, 38]

Low Case (Probability: 20%)

In the low case, the "Win-in-MRD" strategy fails to gain traction against Natera's established commercial machine.[28, 29] Reimbursement for CRC is denied, and biopharma revenue continues to erode as projects move to integrated players like Tempus or Guardant.[5, 14, 32] The company is forced to raise capital at a distressed valuation in 2027.

  • Financial Inputs:
    • Revenue CAGR: 10%.
    • 2030 Revenue: ~$112 million.
    • Gross Margin: 35%.
    • Shares Outstanding: 180 million (significant dilutive rounds).
    • Exit Multiple: 2x EV/Revenue (IP value/distressed sale).
  • Bridge to Valuation: $112M Revenue * 2x = $224M EV.

5-Year Scenario Summary Table

Scenario Rev (Year 5) Margin Assumption Multiple Assumption Implied Share Price 5-Yr Total Return Probability
High Case $530M 70% Gross / 25% Net 10.0x EV/Rev $46.09 +627.0% 25%
Base Case $312M 55% Gross / 15% Net 6.0x EV/Rev $14.40 +127.1% 55%
Low Case $112M 35% Gross / -10% Net 2.0x EV/Rev $1.24 -80.4% 20%
Weighted $326M 12.5% Net Margin 6.2x EV/Rev $19.69 +210.6% 100%

ASYMMETRIC UPSIDE POTENTIAL

6. Qualitative Scorecard:

Each metric is scored on a scale of 1–10 based on current fundamental data and analyst consensus.[32, 40, 50]

  • Management Alignment (8/10): Management is heavily incentivized via performance-based awards tied to clinical reimbursement milestones.[22, 51] CEO Chris Hall and CMO Richard Chen have significant direct ownership, and recent option grants vest over a three-year period, ensuring alignment with long-term shareholders.[52, 53, 54]
  • Revenue Quality (7/10): Improving. The shift from legacy services to recurring clinical diagnostic revenue is a structural positive.[4, 5] However, the current high percentage of unreimbursed tests keeps this score from being higher.[5, 16]
  • Market Position (6/10): Personalis is a "challenger" brand.[28] While it owns the technical high ground (sensitivity), it is currently being out-muscled commercially by Natera.[13, 28, 29] The Tempus partnership is the key to improving this score.[14, 23]
  • Growth Outlook (9/10): The projected 400% clinical volume growth and the expansion into colorectal cancer provide a clear and aggressive growth path.[2, 4, 14]
  • Financial Health (7/10): A $240 million cash balance is strong for a company of this size.[4, 9] However, the $100 million burn rate requires diligent management.[5, 9, 16]
  • Business Viability (7/10): The durability of the business is supported by long-term clinical data (TRACERx).[3] Choke points include the single-partner risk with Tempus and the reliance on a favorable Medicare reimbursement framework.[14, 17, 34]
  • Capital Allocation (7/10): Management has been prudent in raising capital (ATM at $8.43) and is aggressively investing in the highest-ROI area of the business: clinical MRD.[4, 5]
  • Analyst Sentiment (8/10): Consensus is "Moderate Buy" with many analysts raising targets to the $12-$13 range following the Q4 earnings report.[40, 50, 55]
  • Profitability (2/10): Deeply unprofitable with negative margins across the board.[33, 38] Profitability is a "hope" for 2028, not a current reality.[4, 5, 7]
  • Track Record (5/10): The history of shareholder value creation is inconsistent. While the stock has rallied recently, long-term holders have been diluted significantly over the last 5 years.[48, 56, 57]

OVERALL BLENDED SCORE: 6.6

HIGH-CONVICTION CLINICAL CHALLENGER

7. Conclusion & Investment Thesis:

Personalis, Inc. (PSNL) is a high-conviction play on the technical evolution of the liquid biopsy market.[3, 8] The core thesis is built on the superiority of its 1 PPM ultra-sensitive detection, which solves the "low-signal" problem that currently limits the clinical utility of MRD testing in surveillance settings.[10, 11, 12]

Key catalysts for the next 12–24 months include:
1. Revenue Conversion: Transitioning from 16,000+ unreimbursed tests to paid Medicare revenue for breast and lung cancer.[4, 9, 17, 18]
2. CRC Milestone: Securing Medicare coverage for colorectal cancer monitoring, potentially in 2027, following the VICTORI study results.[14, 27, 58]
3. V940 Progress: Positive data or regulatory movement for the Moderna/Merck personalized cancer vaccine, for which Personalis is the primary genomic partner.[7, 21, 47]

The risks are primarily execution-based: securing private payer coverage, managing a high cash burn, and defending against a well-resourced incumbent in Natera.[5, 16, 28] While the path to profitability remains several years away, the company’s fortified balance sheet and explosive clinical volume growth provide a margin of safety for the "Win-in-MRD" strategy to mature.[4, 5, 9]

INFLECTING CLINICAL SCALE

8. Technical Analysis, Price Action & Short-Term Outlook:

PSNL is currently trading at $6.34, significantly underperforming its 200-day moving average of $8.03 and 50-day average of $8.54.[43, 46, 59] The stock has faced heavy selling pressure in March 2026, driven by macro-economic fears and a price target trim from Morgan Stanley to $10.00.[43, 60] Short-term technical indicators like the StochRSI (4.98) suggest the stock is oversold, while the consensus target of $11.50 represents over 80% potential upside.[40, 55, 59] Outlook is neutral-to-bearish in the immediate term until broader market risk appetite for small-cap biotech returns.[43, 60]

OVERSOLD GROWTH ASSET

  1. Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights, https://investors.personalis.com/news-releases/news-release-details/personalis-reports-select-preliminary-fourth-quarter-and-full
  2. Personalis Reports Select Preliminary Fourth Quarter and Full Year ..., https://investors.personalis.com/node/10631/pdf
  3. New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer | Personalis, https://investors.personalis.com/news-releases/news-release-details/new-publication-demonstrates-importance-next-personal
  4. Personalis (NASDAQ: PSNL) details 2025 results and 2026 growth plan - Stock Titan, https://www.stocktitan.net/sec-filings/PSNL/8-k-personalis-inc-reports-material-event-76f5177929c8.html
  5. Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate (NASDAQ:PSNL) | Seeking Alpha, https://seekingalpha.com/news/4558456-personalis-outlines-170-percent-clinical-test-volume-growth-target-for-2026-as-reimbursement
  6. Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker, https://investors.personalis.com/news-releases/news-release-details/personalis-pioneers-advancement-mrd-testing-launch-its-real-time
  7. Personalis Reports Fourth Quarter and Full Year 2024 Financial Results, https://investors.personalis.com/news-releases/news-release-details/personalis-reports-fourth-quarter-and-full-year-2024-financial
  8. Personalis Reports Third Quarter 2025 Financial Results, https://investors.personalis.com/news-releases/news-release-details/personalis-reports-third-quarter-2025-financial-results
  9. Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights, https://www.businesswire.com/news/home/20260226102081/en/Personalis-Reports-Fourth-Quarter-and-Full-Year-2025-Results-and-Recent-Highlights
  10. Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10939476/
  11. MRD Testing, Liquid Biopsy Cancer Assay| Personalis NeXT Personal, https://www.personalis.com/for-biopharma/next-personal/
  12. UNCOMPROMISED MRD PERFORMANCE - Personalis, https://www.personalis.com/wp-content/uploads/2023/10/PRLS505-Next-Personal-Specificity-Study_RGB_R5.00.pdf
  13. Liquid Biopsy | January Round-Up 2025 - DeciBio, https://www.decibio.com/insights/liquid-biopsy-january-round-up-2025
  14. Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients, https://investors.personalis.com/news-releases/news-release-details/personalis-expands-tempus-strategic-collaboration-bring-ultra
  15. Analytical validation of NeXT Personal ® , an ultra-sensitive personalized circulating tumor DNA assay | Oncotarget, https://www.oncotarget.com/article/28565/text/
  16. Personalis (PSNL) Q4 2025 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/02/26/personalis-psnl-q4-2025-earnings-call-transcript/
  17. CMS fixes Medicare reimbursement for Personalis NeXT Personal breast cancer tests, https://www.stocktitan.net/sec-filings/PSNL/8-k-personalis-inc-reports-material-event-4a432b0fca7a.html
  18. Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance, https://investors.personalis.com/news-releases/news-release-details/personalis-receives-medicare-coverage-next-personalr-lung-cancer
  19. Whole-Genome Based MRD Detection - Personalis, https://www.personalis.com/technology/next-generation-ctdna-analytics/whole-genome-mrd/
  20. Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay, https://investors.personalis.com/news-releases/news-release-details/personalis-announces-medicare-coverage-next-dxr-comprehensive
  21. Merck & Moderna's Personalized mRNA Vaccine Sustains 49% Risk Reduction in Melanoma at Five Years | PackGene Biotech, https://www.packgene.com/frontier/012026-merck-modernas-personalized-mrna-vaccine/
  22. [Form 4] Personalis, Inc. Insider Trading Activity - PSNL - Stock Titan, https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-5e529e1eb3a2.html
  23. Personalis and Tempus Expand Collaboration to Biopharma, https://investors.personalis.com/news-releases/news-release-details/personalis-and-tempus-expand-collaboration-biopharma
  24. Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients | Clinical Lab Products, https://clpmag.com/disease-states/cancer/colorectal/personalis-expands-tempus-strategic-collaboration-to-bring-ultra-sensitive-cancer-recurrence-testing-to-colorectal-cancer-patients/
  25. Anti-Cancer MAbS Market Report 2026-2030 Featuring - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/27/3263860/0/en/Anti-Cancer-MAbS-Market-Report-2026-2030-Featuring-Strategic-Analysis-of-Amgen-Bristol-Myers-Squibb-Company-Eli-Lilly-and-Company-Roche-GlaxoSmithKline-and-Other-Key-Players.html
  26. FDA to Review New Drug Combo for Previously Treated Metastatic Colorectal Cancer, https://www.curetoday.com/view/fda-to-review-new-drug-combo-for-previously-treated-metastatic-colorectal-cancer
  27. Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study, https://investors.personalis.com/news-releases/news-release-details/personalis-next-personalr-detects-100-colorectal-cancer-relapses
  28. MRD Test Showdown: clonoSEQ vs Signatera vs Reveal vs Oncodetect | Performance, FDA, Coverage - YouTube, https://www.youtube.com/watch?v=u4o1-nt_KC0
  29. Natera and Personalis Partner for Personalized Monitoring in Oncology, https://investors.personalis.com/news-releases/news-release-details/natera-and-personalis-partner-personalized-monitoring-oncology-0
  30. Signatera™ Genome Clinical Performance Highlighted at ASCO 2025 | Natera, https://www.natera.com/company/news/signateratm-genome-clinical-performance-highlighted-at-asco-2025/
  31. NeoGenomics' PanTracer LBx Test Qualifies for Medicare Coverage Under MolDX Policy, https://clpmag.com/lab-management/company-news/medicare-grants-coverage-blood-based-genomic-profiling-test-advanced-solid-tumors/
  32. Personalis Inc (PSNL) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/psnl/forecast-price-target
  33. PSNL Financials: Income Statement, Balance Sheet & Cash Flow | Personalis - Stock Titan, https://www.stocktitan.net/financials/PSNL/
  34. Personalis receives updated Medicare reimbursement rates for cancer monitoring tests, https://www.investing.com/news/sec-filings/personalis-receives-updated-medicare-reimbursement-rates-for-cancer-monitoring-tests-93CH-4376896
  35. Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights, https://www.biospace.com/press-releases/personalis-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights
  36. PSNL Stock Quote | Price Chart | Volume Chart Personalis - Market Chameleon, https://marketchameleon.com/Overview/PSNL/Summary/
  37. PSNL Personalis, Inc. Earnings Estimates - Seeking Alpha, https://seekingalpha.com/symbol/PSNL/earnings/estimates
  38. Personalis, Inc. Stock Price: Quote, Forecast, Splits & News (PSNL) - Perplexity, https://www.perplexity.ai/finance/PSNL/financials
  39. Personalis Inc 13F Hedge Fund and Asset Management Owners - WhaleWisdom, https://whalewisdom.com/stock/psnl
  40. Personalis (PSNL) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/personalis-inc-consensus-estimates
  41. PSNL / Personalis, Inc. (NasdaqGM) - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/psnl
  42. LCD - MolDX: Next-Generation Sequencing for Solid Tumors (L38121) - CMS, https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38121&ver=11
  43. Personalis, Inc. Stock Price: Quote, Forecast, Splits & News (PSNL) - Perplexity, https://www.perplexity.ai/finance/PSNL?comparing=PSNL,MYGN,TXG,MLAB,TMO,PACB
  44. Who owns Personalis Inc? PSNL Stock Ownership - TipRanks.com, https://www.tipranks.com/stocks/psnl/ownership
  45. Personalis (PSNL) - Trefis, https://www.trefis.com/data/companies/PSNL
  46. Stock Quote & Chart - Investor Relations | Personalis, https://investors.personalis.com/stock-information/stock-quote-chart
  47. Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years, https://www.fiercebiotech.com/biotech/merck-moderna-cancer-vaccine-sustains-49-melanoma-risk-reduction-5-years
  48. Personalis, Inc. Insider Trading & Ownership Structure - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/ownership
  49. PSNL - Personalis, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGM) - Fintel, https://fintel.io/so/us/psnl
  50. Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC - MarketBeat, https://www.marketbeat.com/instant-alerts/filing-personalis-inc-psnl-stake-boosted-by-ark-investment-management-llc-2026-03-05/
  51. PSNL SEC Filings - Personalis 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/PSNL/page-2.html
  52. election of directors - Investor Relations | Personalis, https://investors.personalis.com/static-files/d7d6659f-8582-4eed-9a93-2c1e3fab51cb
  53. Personalis (PSNL) CEO receives major stock option and RSU grants, https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-fec66b99a076.html
  54. Personalis, Inc. (PSNL) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/management
  55. Personalis (PSNL) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/PSNL/forecast/
  56. Personalis (NasdaqGM:PSNL) Stock Forecast & Analyst Predictions - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/future
  57. Personalis Inc (PSNL) Market Cap Today: Live Data & Historical Trends - Public Investing, https://public.com/stocks/psnl/market-cap
  58. Personalis (PSNL) Reveals Promising Interim Results in Colorecta - GuruFocus, https://www.gurufocus.com/news/2809663/personalis-psnl-reveals-promising-interim-results-in-colorectal-cancer-detection-psnl-stock-news?mobile=true
  59. PSNL Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/personalis-inc-technical
  60. Buy Personalis Stock - PSNL Stock Price, Quote & News - SoFi, https://www.sofi.com/invest/stock/PSNL/

View Personalis, Inc. (PSNL) stock page

Loading the interactive version of this report…